A method of hydrolysis of dimethyl succinyl succinate includes: adding DMSS and water to a reactor, and stirring; adding a phase transfer catalyst to the reactor, and heating; and adding an acid and a transition metal salt to the reactor for hydrolysis of DMSS. The acid is sulfuric acid, hydrochloric acid or nitric acid, and the W ion concentration of the mixture in the reactor is 0.2-12 mol/L. The transition metal salt is a nitrate, sulfate, or chloride of copper, nickel, zinc or manganese, or a combination thereof; and the metal ion concentration of the mixture in the reactor is 0.01-0.1 mol/L.

A method of hydrolysis of dimethyl succinyl succinate includes: adding DMSS and water to a reactor, and stirring; adding a phase transfer catalyst to the reactor, and heating; and adding an acid and a transition metal salt to the reactor for hydrolysis of DMSS. The acid is sulfuric acid, hydrochloric acid or nitric acid, and the W ion concentration of the mixture in the reactor is 0.2-12 mol/L. The transition metal salt is a nitrate, sulfate, or chloride of copper, nickel, zinc or manganese, or a combination thereof; and the metal ion concentration of the mixture in the reactor is 0.01-0.1 mol/L.

The present disclosure is directed to novel derivatives of terpenes, particularly ester derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

A compound includes, in a molecule, a structure A represented by the following A and a structure B represented by the following B, in which the compound includes two or more of the structures B in the molecule. A: A structure in which at least one or more aromatic ring structures are included and a total number of π electrons of the aromatic ring structure in the molecule is 8 or more. However, an aryl amine structure represented by a predetermined structure is excluded. B: A fluorine-containing terminal structure represented by a predetermined structural formula.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Biologically active cannabidiol analogs comprising a compound of the formula ##STR00001##
wherein one of R.sub.1 or R.sub.2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R.sub.1 or R.sub.2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R.sub.1 or R.sub.2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

A lubricity modifier for fuels contain a dicarboxylic acid monoester compound represented by formula (I). In formula (I), R.sub.1 represents a single bond, a substituted or unsubstituted C.sub.2-6 divalent alkenyl group, or a group having a structure of —R.sub.3—R.sub.4—R.sub.5—; R.sub.2 represents a substituted or unsubstituted C.sub.1-40 hydrocarbyl group; R.sub.3 and R.sub.5 each independently represents a single bond, or a substituted or unsubstituted C.sub.1-3 divalent alkyl group; and R.sub.4 represents a substituted or unsubstituted C.sub.3-12 divalent alicyclic group.

##STR00001##